Literature DB >> 23769317

Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.

Christopher Cao1, David H Tian2, Kristopher A Pataky2, Tristan D Yan3.   

Abstract

INTRODUCTION: Pleurectomy/decortication (P/D) in the treatment of malignant pleural mesothelioma includes a number of procedures with different clinical indications and therapeutic intents. To unify the nomenclature, IMIG and IASLC recently defined P/D-related procedures according to surgical technique, including 'extended P/D', 'P/D' and 'partial pleurectomy'. The present systematic review aimed to assess the safety and efficacy of these techniques.
METHODS: A systematic review of relevant studies was performed by electronic search of five online databases from 1985 to 2012 by two independent reviewers according to predefined selection criteria.
RESULTS: Thirty-four studies involving 1916 patients who underwent pleurectomy were included for quantitative analysis. These included 12 studies on 'extended P/D', 8 studies on 'P/D' and 14 studies on 'partial pleurectomy'. Perioperative mortality ranged from 0% to 11% and perioperative morbidity ranged from 13% to 43%. Median overall survival ranged from 7.1 to 31.7 months and disease-free survival ranged from 6 to 16 months. One study reported on quality-of-life outcomes using a standardized questionnaire suggesting superior outcomes for 'extended P/D' compared to extrapleural pneumonectomy.
CONCLUSIONS: Results of the present systematic review suggested similar perioperative mortality outcomes between different P/D techniques but a trend towards higher morbidity and length of hospitalization for patients who underwent 'extended P/D'. However, overall and disease-free survival appeared to favour 'extended P/D' compared to less aggressive techniques. Future studies on P/D should adhere to recent definitions to enable accurate analysis of similar procedures. Direct comparisons of pleurectomy to extrapleural pneumonectomy remain challenging, and should be restricted to 'extended P/D' procedures only.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Mesothelioma; Pleurectomy; Systematic review

Mesh:

Year:  2013        PMID: 23769317     DOI: 10.1016/j.lungcan.2013.04.024

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  12 in total

1.  Mesothelioma diagnosis and prognosis, are we moving beyond histology and performance status towards circulating biomarkers?

Authors:  Oluf Dimitri Røe
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

2.  Surgical controversies in mesothelioma: MesoVATS addresses the role of surgical debulking.

Authors:  Chuong D Hoang
Journal:  Transl Lung Cancer Res       Date:  2016-02

3.  Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.

Authors:  Egesta Lopci; Paolo Andrea Zucali; Giovanni Luca Ceresoli; Matteo Perrino; Laura Giordano; Letizia Gianoncelli; Elena Lorenzi; Maria Gemelli; Armando Santoro; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-18       Impact factor: 9.236

4.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

Review 5.  Hedgehog Signaling in Malignant Pleural Mesothelioma.

Authors:  Emanuela Felley-Bosco; Isabelle Opitz; Mayura Meerang
Journal:  Genes (Basel)       Date:  2015-07-08       Impact factor: 4.096

6.  Multiple distant metastases in a case of malignant pleural mesothelioma.

Authors:  Kemal Can Tertemiz; Aylin Ozgen Alpaydin; Duygu Gurel; Recep Savas; Aytac Gulcu; Atila Akkoclu
Journal:  Respir Med Case Rep       Date:  2014-08-08

7.  A Rare Case of Malignant Pleural Mesothelioma with Metastases to the Pancreas Concurrently Diagnosed with Invasive Ductal Adenocarcinoma.

Authors:  Chelsea Wuthnow; Yasmine Hussein Agha; Sachin Srinivasan; William Salyers; Nathan Tofteland
Journal:  Kans J Med       Date:  2020-10-20

8.  Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG).

Authors:  Mir Alireza Hoda; Thomas Klikovits; Madeleine Arns; Karin Dieckmann; Sabine Zöchbauer-Müller; Christian Geltner; Bernhard Baumgartner; Peter Errhalt; Barbara Machan; Wolfgang Pohl; Jörg Hutter; Josef Eckmayr; Michael Studnicka; Martin Flicker; Peter Cerkl; Walter Klepetko
Journal:  Wien Klin Wochenschr       Date:  2016-07-25       Impact factor: 1.704

9.  Management of malignant pleural mesothelioma - part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database.

Authors:  Thomas Klikovits; Mir Alireza Hoda; Yawen Dong; Madeleine Arns; Bernhard Baumgartner; Peter Errhalt; Christian Geltner; Barbara Machan; Wolfgang Pohl; Jörg Hutter; Josef Eckmayr; Michael Studnicka; Martin Flicker; Peter Cerkl; Klaus Kirchbacher; Walter Klepetko
Journal:  Wien Klin Wochenschr       Date:  2016-07-25       Impact factor: 1.704

10.  Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma.

Authors:  Eric Lim; Liz Darlison; John Edwards; Daisy Elliott; D A Fennell; Sanjay Popat; Robert C Rintoul; David Waller; Clinton Ali; Andrea Bille; Liz Fuller; Andreea Ionescu; Manjusha Keni; Alan Kirk; Pek Koh; Kelvin Lau; Talal Mansy; Nick A Maskell; Richard Milton; Dakshinamoorthy Muthukumar; Tony Pope; Amy Roy; Riyaz Shah; Jonathan Shamash; Zacharias Tasigiannopoulos; Paul Taylor; Sarah Treece; Kate Ashton; Rosie Harris; Katherine Joyce; Barbara Warnes; Nicola Mills; Elizabeth A Stokes; Chris Rogers
Journal:  BMJ Open       Date:  2020-09-01       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.